Bro's VerdictDeep Dive
Rating
BUY
Confidence
60%
Target Price
A$210.00
Upside
+13.8%
Horizon
medium
CSL is a high-quality plasma franchise undergoing a self-inflicted reset, with immunoglobulin growth (+14% H2) and gross margin recovery from yield initiatives supporting a base case fair value of ~$210 (21x NTM EPS). The stock trades at 18.4x forward earnings versus a 2-year average of 38.6x, but the discount partly reflects depressed trailing earnings and a guided -9.9% forward EPS decline. With ~14% upside to the base case and balanced risk/reward after a +50% three-month rally, I rate it a moderate buy, preferring to add on pullbacks toward $160-$170.
Executive Summary
Financial Snapshot
Forward Outlook
Valuation Analysis
Peer Comparison
Key Risks & Catalysts
Risks
Catalysts
Investment Thesis
CSL is a high quality plasma and vaccines franchise working through a self inflicted reset. The $7.1b impairment and Vifor guidance cut have cleared the decks, and the market has rewarded the guidance beat with a +50% three month rally. At 18.4x forward earnings against a 2y average of 38.6x, the multiple looks cheap, but that comparison flatters a business whose trailing earnings are artificially depressed and whose forward EPS is still forecast to fall -9.9%.
The recovery case rests on three levers: immunoglobulin growth (already +14% in H2), plasma yield and cost per litre improvements lifting gross margin from 51.1%, and gene therapy plus Andembry launches adding a higher margin tail. Vifor remains the drag, with a ~25% revenue decline guided, so group EBIT of ~$6.9b is the number to watch.
I rate CSL a moderate buy with a $210 base case target, implying ~14% upside. Risk/reward is balanced given the recent rerating; I would add on any pullback toward $160 to $170, where the EV/EBIT and EV/EBITDA implied prices cluster. The key swing factors are Vifor stabilisation and the gross margin trajectory through FY27.